聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察

doi:10.3969/j.issn.1672-5069.2012.02.014

实用肝脏病杂志 ›› 2012, Vol. 15 ›› Issue (2): 123-125.doi: 10.3969/j.issn.1672-5069.2012.02.014

聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察

朱义玲, 陈丽, 赵卫峰, 甘建和

215006 江苏省苏州市苏州大学附属第一医院感染病科

收稿日期:2011-10-09 出版日期:2012-04-10 发布日期:2017-03-07
通讯作者: 赵卫峰,E-mail:szzhaoweifeng@yahoo.com.cn
作者简介:朱义玲女,28岁,大学本科,检验师。E-mail:eileenzhu11@sina.com

Observation on the efficacy of peginterferon and ribavirin in the treatment of patients with chronic hepatitis C

Zhu Yiling, Chen Li, Zhao Weifeng, et al.

Department of Infectious Disease,the First Affiliated Hospital,Suzhou University, Suzhou 215006,China

Received:2011-10-09 Online:2012-04-10 Published:2017-03-07

摘要/Abstract

摘要： 目的评价聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎的临床疗效。方法使用聚乙二醇干扰素α-2a（派罗欣）联合利巴韦林（800~1200mg/d）治疗58例慢性丙型肝炎患者,疗程48周,分别于治疗12周、24周和48周及治疗结束后24周评价疗效,并观察药物副作用。结果基因1型和非基因1型患者早期应答率分别为57.1%和76.7%（P>0.05）,持续应答率分别为53.6%和80.0%（P<0.05）;HCV RNA高水平组和低水平组之间持续应答率分别为56.3%和80.8%,具有显著性差异（P<0.05）。结论在慢性丙型肝炎患者的治疗中,基因1型患者疗效低于非基因1型,HCV RNA低水平组的疗效优于高水平组。

关键词: 慢性丙型肝炎, 聚乙二醇干扰素, 利巴韦林, 治疗

Abstract: Objective To evaluate the clinical effects of combination of peginterferon and ribavirin in the treatment of patients with chronic hepatitis C. Method 58 patients with chronic hepatitis C received a combination of Pagasys（180μg/week）and ribavirin（800~1200mg/d）for 48 weeks. Liver function and level of HCV RNA were determined at the 12th,24th and 48th week during the treatment. Result The early virological response （EVR）rates and sustained virological response（SVR）rates in patients with genotype 1 were 57.1% and 53.6%,but in genotype non-1 patients those were 76.7% and 80%,respectively（P<0.05）;the early virological responserate in patients with high serum HCV RNA level was 56.3%,much lower than 80.8%（P<0.05）in patients with low serum HCV RNA level. Conclusion The response to the combination treatment in patients with chronic hepatitis C is influenced by genotype and the serum level of HCV RNA.

Key words: Hepatitis C, Peginterferon（α-2a）, Ribavirin, Therapy

朱义玲, 陈丽, 赵卫峰, 甘建和. 聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察[J]. 实用肝脏病杂志, 2012, 15(2): 123-125.

Zhu Yiling, Chen Li, Zhao Weifeng, et al.. Observation on the efficacy of peginterferon and ribavirin in the treatment of patients with chronic hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(2): 123-125.

参考文献

[1] Perz JF,Armstrong GL,Farrington LA,et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol,2006,45（4）：529-538.
[2] Ghany MG,Strader DB,Thomas DL,et al. Diagnosis,management and treatment of hepatitis C：all update. Hepatology,2009,49（4）：1335-1374.
[3] 中华医学会传染病与寄生虫病学分会和肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,8（4）:324-329.
[4] 张英,朱建英,曾丽娇,等. 聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎. 热带医学杂志,2008,8（8）：810-812.
[5] Carithers RL,Emerson SS. Therapy of hepatitis C：meta-analysis of interferon alfa-2b trials. Hepatology,1997,26（3 Suppl 1）:83S-88S.
[6] Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet,1990,19（5）：390-399.
[7] Neumann AU,Lam NP,Dahari H,et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science,1998,282（5386）：103-107.
[8] Yamada G,Takatani M,Kishi F,et al. Efficacy of interferon alfa therapy in chronic hepatitis C virus RNA level. Hepatology,1995,22：1351.
[9] Orito E,Mizokami M,Suzuki K,et al. Loss of serum HCV RNA at week 4 of interferon-α therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol,1995,46：109.
[10] Ge D,Fellay J,Thomason AJ,et al. Genetic variation in IL28B predicts hepatitis C treatment induced viral clearance. Nature,2009, 461（7262）：399-401.
[11] Hayes CN,Kobayashi M,Akuta N. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut, 2011,60（2）：261-267.
[13] 廖祥伟,凌云,李新华,等. 宿主IL28B基因型联合病毒基因型对慢性丙型肝炎抗病毒疗效的预测.中国病毒病杂志,2011,1：35-40.

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[7]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[8]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[9]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[10]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[11]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[12]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[13]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[14]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[15]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.

聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察

Observation on the efficacy of peginterferon and ribavirin in the treatment of patients with chronic hepatitis C

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价